Latest Commercialisation News

Amplia Therapeutics reported a $4.18 million half-year loss but bolstered its cash reserves with a $27.6 million capital raise to advance clinical trials of its lead drug narmafotinib, showing encouraging interim data in pancreatic cancer.

Reward Minerals has secured 100% ownership of the Copper Lance Project in Newfoundland, initiating field sampling to validate historic high-grade copper, silver, and gold mineralisation. The project reveals multiple undrilled anomalies and new exploration targets in a prolific VMS district.

Recce Pharmaceuticals has secured a key patent in Hong Kong for its synthetic anti-infectives, reinforcing its intellectual property footprint in Asia and supporting its clinical and commercial ambitions in the region.

Altech Batteries has completed the final design of its next-generation Sodium Nickel Chloride UPS battery system, setting the stage for factory testing and trial deployments across the Netherlands. This milestone marks a significant step toward broader European commercialisation.

ReNerve Ltd reports a strong 53% year-on-year revenue increase, expanding its US distribution network and advancing clinical studies for its nerve repair products. The company is poised for significant global market growth with new partnerships and upcoming product launches.

Redivium Limited has advanced its battery recycling ambitions with a binding offtake agreement alongside strategic funding plans, despite ongoing ASX suspension. The company’s new partnership with WMC Energy BV marks a pivotal step toward commercialising its UK recycling facility.

Algorae Pharmaceuticals has secured a key distribution agreement with global giant Dr. Reddy’s Laboratories to supply the chemotherapy drug Capecitabine in Australia, marking a significant step in its oncology commercialisation strategy.

Audeara Limited has achieved a key regulatory milestone with NMPA certification in China, paving the way for commercial launch of its hearing personalisation technology through a leading e-commerce brand. This approval supports the company’s strategy to generate scalable licensing revenue in a rapidly growing market.

EMVision Medical Devices has begun a pivotal aeromedical study with the Royal Flying Doctor Service to test its portable First Responder brain scanner in remote emergency settings. The trial aims to validate device usability and workflow integration ahead of commercial rollout.

Provaris Energy’s 2025 AGM highlights strategic progress in hydrogen and CO2 storage technologies, focusing on European market expansion and a refined licensing business model.

PPK Group reports record revenue at Craig International Ballistics and advances lithium sulfur battery technology, while preparing for a CEO transition and focusing on sovereign manufacturing.

Proteomics International secures a key Medicare reimbursement rate for its PromarkerD test, a predictive diagnostic for diabetic kidney disease, marking a critical step in its US commercial rollout.